Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: Effect of disease and therapy

Clinics

Volumn 68, Issue 2, 2013, Pages 129-133

  Miossi, Renata ^a   Fuller, Ricardo ^a   Moraes, Júlio C B ^a   Ribeiro, Ana Cristina M ^a   Saad, Carla G S ^a   Aikawa, Nadia E ^a   Miraglia, João L ^b   Ishida, Maria A ^a   Bonfá, Eloisa ^a   Caleiro, M Teresa C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

H1N1 subtype; Influenza A virus; Influenza vaccine; Mixed connective tissue disease

Indexed keywords

INFLUENZA VACCINE;

ADULT; ARTICLE; CASE CONTROL STUDY; FEMALE; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; NONPARAMETRIC TEST; TIME;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84875680305     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(02)OA02     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention. Questions and Answers: Vaccine Selection for the 2010-2011 Influenza Season. http://www.cdc. gov/flu/about/qa/1011_vac_selection.htm (accessed 10 August 2011).
2. Centers for Disease Control and Prevention. Questions and Answers: Vaccine Selection for the 2011-2012 Influenza Season. http://www.cdc. gov/flu/about/qa/vaccine-selection.htm (accessed 10 august 2011).
3. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414-22, http://dx.doi.org/10.1136/ard.2010.137216.
4. Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicenter, double-blind, randomized, placebo-controlled trial. Lancet. 2010;375(9708):56-66, http://dx.doi.org/10.1016/S0140-6736(09) 62003-1.
5. Saad CGS, Borba EF, Aikawa NE, Silva CA, Pereira RM, Calich AL, et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic disease. Ann Rheum Dis. 2011;70(6):1068-73, http://dx.doi.org/10.1136/ard.2011. 150250.
6. Kasukawa R. Mixed connective tissue disease. Intern Med. 1999;38(5):386-93, http://dx.doi.org/10.2169/internalmedicine.38.386.
7. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):544-58.
8. Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res. 2011;63(7):1062-67, http://dx.doi.org/10.1002/acr.20465.
9. Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, et al. Glucocorticoid: Major Factor for Reduced Immunogenicity of 2009 Influenza A (H1N1) Vaccine in Patients with Juvenile Autoimmune Rheumatic Disease. J Rheumatol. 2012;39(1):167-73, http://dx.doi.org/10.3899/jrheum.110721.
10. Wiesik-Szewczyk E, Romanowska M, Mielnik P, Chwalińska-Sadowska H, Brydak LB, Olesińska M, et al. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin Rheumatol. 2010;29(6):605-13, http://dx.doi. org/10.1007/s10067-010-1373-y.
11. Holvast B, Huckriede A, Kallenberg CG, Bijl M. Influenza vaccination in systemic lupus erythematosus: safe and protective? Autoimmun Rev. 2007;6(5):300-5, http://dx.doi.org/10.1016/j.autrev.2006.09.012.
12. Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, et al. Specific antibody response after influenza immunization in systemic lupus erythematous. J Rheumatol. 2002;29(12):2555-7.
13. Shoenfeld Y, Agmon-Levin N. 'ASIA'-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4-8, http://dx.doi.org/10.1016/j.jaut.2010.07.003.
14. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine. 2009;27(49):6959-65, http://dx. doi.org/10.1016/j.vaccine.2009.08.101.
15. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005;19(5):685-708, http://dx.doi.org/10. 1016/j.berh.2005.03.010.
16. Swaak AJ, Groenwold J, Aarden LA, Statius van Eps LW, Feltkamp EW. Prognostic value of anti-dsDNA in SLE. Ann Rheum Dis. 1982;41(4):388-95, http://dx.doi.org/10.1136/ard.41.4.388.
17. Lu CC, Wang YC, Lai JH, Lee TS, Lin HT, Chang DM. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: Safety and immunity. Vaccine. 2011;29:444-50, http://dx.doi.org/10.1016/j.vaccine. 2010.10.081.
18. Urowitz MB, Anton A, Ibanez D, Gladman DD. Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus, Arthritis Care Res (Hoboken). 2011;63(11):1517-20, http://dx.doi.org/10.1002/acr.20599.
19. Mathian A, Devilliers H, Krivine A, Costedoat-Chalumeau N, Haroche J, Huong DB. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthritis Rheum. 2011;63(11):3502-11, http://dx. doi.org/10.1002/art.30576.
20. Bickel M, von Hentig N, Wieters I, Khaykin P, Nisius G, Haberl A, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 2011;52(1):122-7, http://dx.doi.org/10.1093/cid/ciq003.
21. Borba EF, Saad CGS, Pasoto SG, Calich AL, Aikawa NE, Ribeiro AC, et al. Influenza A/H1N1 vaccination of patients with SLE: can anti-malarial drugs restore diminished response under immunossupressive therapy? Rheumatology(Oxford). 2012;51(6):1061-9, http://dx.doi.org/10.1093/rheumatology/ker427.
22. Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvantfree vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis. 2011;70(12):2144-7, http://dx.doi.org/10.1136/ard.2011.152983.
23. Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-addjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011;63:1486-96, http://dx.doi.org/10.1002/art.30325.